For medical oncologists navigating the landscape of cellular immunotherapy, the conversation around cancer relapse has shifted from if to when: and more importantly, how often we can intervene. While autologous CAR-T therapies have demonstrated remarkable initial response rates in hematologic malignancies, the durability question remains unresolved. iPSC-derived cell therapy represents a fundamental departure from this … Continue reading Why iPSC-Derived Cell Therapy is the “Long Game” for Cancer Relapse